Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia

Gertjan J.L. Kaspers, Jelle J.M. Wijnands, Reinhard Hartmann, Loekie Huismans, Anne H. Loonen, Arend Stackelberg, Guenter Henze, Robrecht Pieters, Karel Hählen, Elisabeth R. Van Wering, Anjo J.P. Veerman

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

28 Citaten (Scopus)


At relapse, T-cell acute lymphoblastic leukaemia (ALL) has a worse patient outcome than B-cell precursor (BCP-) ALL. To investigate this further, we compared in vitro cellular drug resistance profiles of T-cell and BCP-ALL samples obtained at relapse. We investigated 237 paediatric relapsed ALL cases, including 151 samples taken at first relapse, of which 30 were T-cell ALL. In vitro drug resistance was measured using the 4-day methyl-thiazol-tetrazolium (MTT) assay and cellular immunophenotype was determined at central reference laboratories. Similar results were found for first relapsed ALL samples and for the total group: T-cell ALL samples were more resistant to 4-HOO-ifosfamide (1.4-fold, P = 0.019) and cisplatin (3.7-fold, P = 0.005). The samples were more sensitive to thiopurines such as mercaptopurine (2.1-fold, P = 0.007) and thioguanine (1.7-fold, P = 0.003). Resistance/sensitivity to 16 other drugs did not differ significantly. These results do not explain the relatively poor prognosis of T-cell ALL at relapse, but do suggest that the more intensive use of thiopurines in relapsed T-cell ALL may be beneficial.

Originele taal-2Engels
Pagina's (van-tot)1300-1303
Aantal pagina's4
TijdschriftEuropean Journal of Cancer
Nummer van het tijdschrift9
StatusGepubliceerd - jun. 2005
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia'. Samen vormen ze een unieke vingerafdruk.

Citeer dit